X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis, in the US.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radius Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 19, 2023
Details:
Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of osteoarticular metabolism.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abiogen Pharma S.p.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
